When do the MIDAZOLAM HYDROCHLORIDE (AUTOINJECTOR) patents expire, and when will generic MIDAZOLAM HYDROCHLORIDE (AUTOINJECTOR) be available?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Rafa Labs Ltd	MIDAZOLAM HYDROCHLORIDE (AUTOINJECTOR)	midazolam hydrochloride	SOLUTION;INTRAMUSCULAR	216359-001	Aug 8, 2022		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: July 18, 2026

Midazolam hydrochloride autoinjectors sit at the intersection of emergency neurology and competitive access dynamics in acute care. The investment case hinges on (1) whether the product is on a widely adopted formulary pathway for seizure rescue, (2) exclusivity runway driven by Orange Book and related patents, (3) exposure to generic substitution risk for both device-delivery and drug labeling, and (4) litigation and regulatory barriers to true-to-label generic or ANDA entry. This analysis maps the core commercial and IP fundamentals an investor should underwrite.

What patents protect midazolam hydrochloride autoinjector products in the US?

Answer: Patent protection typically clusters into three buckets: (1) composition and salts (midazolam HCl), (2) formulation and device-integrated delivery (especially autoinjector-specific subassemblies, fill/hold, and stability), and (3) method-of-use tied to seizure termination and emergency administration. For a credible investment model, the decisive question is not whether midazolam is patented, but whether the autoinjector’s device-integrated product and label-defined use remain protected as of the investment horizon.

Patent estate structure to underwrite

1) Drug substance and composition patents

Claims covering midazolam hydrochloride itself are often earlier generation and likely expired or near-expiry depending on specific claim sets and jurisdictions.
In practice, investors should treat “midazolam HCl” substance patents as base-line risk, then shift weight to formulation and device claims.

2) Formulation and stabilization patents

Autoinjectors impose stability and viscosity constraints. Patent claims often cover:

Solvent system and pH window
Buffering agents
Antioxidant and stabilizer selections
Preservative strategy (if applicable)
Shelf-life and stress conditions compatible with autoinjector storage

3) Autoinjector device and delivery system patents

Typical device claim themes include:

Needle deployment mechanics
Spring geometry and safety features
Sleeve/trigger design
Drug containment (cartridge) configurations
Tamper resistance and needle retraction
Operational dose accuracy parameters

Underwriting point: even if a generic ANDA is possible for the solution, a device-delivery pathway can still create a “practical exclusivity” layer if the generic cannot replicate the injection performance, safety features, or shelf-stability through the same device interface.

4) Method-of-use and labeling-related patents

For seizure rescue, claims may be drafted to cover:

Administration route and timing (rapid rescue)
Patient population and seizure type language
Concomitant settings like emergency or pre-hospital administration

Underwriting point: method-of-use patents do not block FDA approval, but they affect potential litigation exposure for generic manufacturers and biosimilar-like “authorized” entrants.

Which jurisdictions matter

US: Orange Book listings and patent infringement exposure under 35 U.S.C. §271.
Europe: national patent enforcement and EU regulatory exclusivity, plus device conformity constraints.
Key commercial markets: US, UK, Germany, France, Italy, Spain, Canada, and selected APAC markets where emergency seizure rescue adoption is rising.

When does midazolam hydrochloride autoinjector lose exclusivity?

Answer: For midazolam rescue products, exclusivity is usually a composite of:

Orange Book patent expirations tied to the drug product and any listed device-connected patents,
FDA exclusivity types if applicable (data exclusivity and pediatric exclusivity),
device-industry lock-in if the generic cannot achieve label-equivalent performance.

Decision rule for investors: model exclusivity loss on the latest relevant listed patent that is enforceable and materially read on a generic defendant’s product.

Key timing levers to build into an investment model

Orange Book patent expiration date(s): hardest gating item for Paragraph IV ANDA risk assessments.
Pediatric exclusivity (if applicable): can extend by 6 months from base expiration depending on timing and required studies.
Market exclusivity vs patent exclusivity: many midazolam products are older; exclusivity may be exhausted even if patents remain.

What investors should focus on for runway

Patent claims tied to device-integrated delivery can delay generic substitution even after drug substance coverage ends.
Patent claims tied to specific stabilization can also matter for shelf-life and product handling in autoinjector form factors.

What is the Orange Book status of midazolam hydrochloride autoinjector?

Answer: Orange Book status determines whether an ANDA route for a generic midazolam autoinjector is blocked by listed patents and whether Paragraph IV certifications are feasible.

How to interpret Orange Book listings for device-delivery products

If patents listed include “drug substance,” “drug product,” and “use,” expect a multilayer enforcement landscape.
If device-integrated formulation patents are listed, that increases the cost of generic equivalency arguments and raises litigation probability.

Investment implication

Orange Book depth (number of listed patents with relevant claims) is a leading indicator for:
- anticipated settlement costs,
- likelihood of no-ATB or delayed entry,
- and the probability of “launch-at-risk” outcomes.

How many patents cover midazolam hydrochloride autoinjector formulations and device delivery?

Answer: Patent counts are the practical proxy for litigation and settlement risk. For device-delivery rescue products, estates commonly exceed pure-solution estates because they cover formulation plus injection mechanics.

How to categorize patent coverage for an investment underwriting

Drug product/formulation: formulation, stability, concentration range, and container interface compatibility.
Device: injection mechanism, safety, needle deployment and retraction.
Use: emergency administration, timing, and patient context.

How counts map to commercial outcomes

High counts plus broad claims generally mean:
- more settlements,
- more “skinny label” or partial design-around attempts,
- higher likelihood the product retains pricing power longer.

What patent litigation affects midazolam hydrochloride autoinjector investors?

Answer: Litigation is typically driven by ANDA Paragraph IV certifications once Orange Book coverage is challenged. For an autoinjector, disputes often expand beyond the drug solution into device performance and labeling equivalence.

What to look for in docket-level risk scoring

Paragraph IV filings and the number of challengers
Whether claims asserted are formulation, device, or use
Settlement types:
- “launch” agreements (generic begins at a date),
- “no-AG” provisions (often restricting marketing timing),
- or design-around agreements.

Why the autoinjector form factor increases risk

Device substitution can be treated as non-equivalent if performance and safety features differ.
Even if a generic obtains FDA approval, infringement exposure may persist depending on claim scope.

What generic entry risks exist for midazolam hydrochloride autoinjector?

Answer: Generic entry risk depends on whether an ANDA can be approved for a product that is:

chemically equivalent (midazolam HCl solution),
pharmaceutically equivalent in delivery (device interface compatibility and dose accuracy),
label-equivalent (seizure rescue instructions and indications).

ANDA feasibility risk map

Chemical equivalence: usually lower risk if midazolam HCl is generic in bulk.
Formulation and stability: higher risk because autoinjector storage conditions are stringent.
Device integration: may require a branded device or a complex design-around.
Label equivalence: if device delivery changes administration steps, labeling disputes can constrain substitution.

Commercial risk outcome scenarios

Soft risk: generic enters with partial restrictions or design-around, limiting uptake.
Hard risk: launch-at-risk followed by settlement, then accelerated pricing pressure.
No risk: generic cannot meet device-integrated performance or infringes active patents.

How does midazolam autoinjector compare with alternative seizure rescue therapies for investment positioning?

Answer: Midazolam autoinjectors compete in seizure rescue against other rapid-acting options and delivery routes. Investors should benchmark:

onset and real-world administration usability,
formulary preference by hospital systems,
and contract pricing dynamics for emergency supplies.

Competitive axis to underwrite

Delivery route and training burden (autoinjector vs nasal vs rectal)
Target setting (home, school, EMS, hospital)
Bulk procurement cycles (large health systems and public health contracts)
Payer coverage and prior authorization patterns

Strategic implication

Even where generics exist for midazolam products, payer and provider adoption can remain sticky if the autoinjector improves speed and reduces administration errors. That shifts value toward distribution execution as much as toward pure patent duration.

What formulations are protected by midazolam hydrochloride autoinjector patents?

Answer: Formulation protection usually targets the buffered midazolam HCl solution used inside the autoinjector cartridge, with claims spanning concentration, excipient choices, pH control, and stability compatibility with needle deployment and storage.

Typical claim elements that matter commercially

Midazolam concentration range that is operationally compatible with dose delivery volume
Buffer system designed to resist pH drift
Stabilizers to reduce degradation under temperature cycling
Compatibility with container/closure and cartridge polymers

Design-around likelihood

If claims are narrow to specific excipient combinations, generics can sometimes substitute an alternative buffering system while preserving equivalence.
If claims are broader to functional parameters (pH and stability outcomes), design-around becomes harder and litigation more frequent.

What method-of-use patents cover seizure rescue with midazolam autoinjectors?

Answer: Method-of-use protection typically tracks emergency administration context and timing, including:

administration at seizure termination attempts,
rapid rescue workflows in pre-hospital and emergency department settings,
and patient population descriptors consistent with labeling.

Investment impact

Method-of-use patents can:

deter early generic marketing,
increase settlement likelihood even when formulation/device claims are manageable.

What FDA regulatory pathway governs midazolam hydrochloride autoinjectors, and how does it affect exclusivity?

Answer: The reference product’s regulatory basis determines what an ANDA competitor must do to enter and whether they can pursue Paragraph IV against listed patents.

Regulatory underwriting points

Whether the original approval relied on clinical data packages that are eligible for exclusivity protection
Whether the generic route is ANDA (small molecule) vs a device-integrated path requiring additional evidence
Whether the labeling is tied closely to device operation steps, raising label-equivalence barriers

Which companies hold licensing deals or manufacturing/IP access for midazolam autoinjectors?

Answer: Investment relevance centers on whether the autoinjector manufacturing partner(s) and device IP licensors restrict scale-up or require royalties that compress gross margin for incumbents after exclusivity weakens.

What matters in licensing for the investment model

Who owns device patents vs who owns the drug product
Whether the autoinjector cartridge is proprietary
Whether contract manufacturing includes royalty pass-through terms
Whether there are exclusivity-like supply agreements that delay generic adoption

What is the commercial adoption outlook for midazolam hydrochloride autoinjectors?

Answer: The adoption curve is driven by emergency usability, purchasing channel strength, and institutional protocols for seizure rescue.

Commercial fundamentals to model

Hospital and EMS uptake: formulary inclusion and stocking frequency
Community adoption: pharmacy reimbursement patterns and patient support programs
Contracting: government and school-based procurement where seizure rescue needs are standardized
Inventory cycles: autoinjector brands can be penalized by supply interruptions more than solution-only formats

Investment scenario: base case, downside, upside for midazolam autoinjector

Answer: A practical scenario framework uses two variables: exclusivity runway (patent/Orange Book coverage) and competitive pressure (generic or device-equivalent substitution).

Base case (moderate competitive pressure)

Product retains meaningful share while exclusivity holds.
Uptake expands via institutional contracts and training programs.
Pricing pressure is gradual; margin compression occurs after distribution normalization.

Downside (earlier-than-modeled entry or aggressive Paragraph IV)

Generic competitor(s) file Paragraph IV and force litigation/settlement leverage.
Entry occurs with a label and device design that is accepted by payers and providers.
Gross margin declines faster due to contract repricing.

Upside (extended device/formulation protection or limited substitution)

Device-integrated patents and formulation stability claims hold up, delaying generic substitution.
Autoinjector retains a differentiated workflow and payer support.
Revenue compounds via home and community channels.

Key Takeaways

Midazolam hydrochloride autoinjector investment value depends less on midazolam as a chemical and more on device-integrated formulation, injection mechanics, and Orange Book-listed enforceable patents.
Build exclusivity runway on the last enforceable listed patent that read on a device-equivalent ANDA product.
Generic substitution risk is elevated if formulation/device claims are narrow or easy to design around; it is reduced if device delivery performance and cartridge stability are tightly claimed.
Competitive positioning is driven by adoption and workflow fit in emergency and seizure rescue settings, which can mitigate price erosion even after chemical-level generic availability.
The highest underwriting risk is Paragraph IV litigation leading to earlier settlement-based entry and payer-driven substitution.

FAQs

Do midazolam hydrochloride autoinjectors have Orange Book-listed patents that can be challenged via Paragraph IV?
What is the biggest generic barrier for an autoinjector versus a conventional vial of midazolam hydrochloride?
How do method-of-use seizure rescue patents affect generic launch timing even after FDA approval?
What revenue concentration risks arise from emergency supply contracts for autoinjector products?
How should investors model device-integrated IP royalties when exclusivity expires?

References (APA)

FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
FDA. (n.d.). Drug Approval and Databases: Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
FDA. (n.d.). ANDA (Abbreviated New Drug Application). https://www.fda.gov/drugs/abbreviated-new-drug-application-anda

US Patents:	0
Applicants:	1
NDAs:	1

AI Deep Research

Questions you can ask:

Summary for MIDAZOLAM HYDROCHLORIDE (AUTOINJECTOR)